{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=14", "query": { "condition": "Relapsed/Refractory", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 3665, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T01:09:27.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05571787", "title": "HMPL-523 Food Effect and Proton Pump Inhibitor Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Lymphoma" ], "interventions": [ { "name": "HMPL-523", "type": "DRUG" }, { "name": "Rabeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 26, "start_date": "2022-07-13", "completion_date": "2022-09-22", "has_results": false, "last_update_posted_date": "2023-02-23", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05571787" }, { "nct_id": "NCT03318016", "title": "Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Relapsed/Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cyclophosphamide 500 MG", "type": "DRUG" }, { "name": "Cyclophosphamide 1000 MG", "type": "DRUG" }, { "name": "Cyclophosphamide 2000 MG", "type": "DRUG" }, { "name": "Cyclophosphamide 3000 MG", "type": "DRUG" }, { "name": "Cyclophosphamide 4000 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5, "start_date": "2017-12-15", "completion_date": "2021-01-20", "has_results": true, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03318016" }, { "nct_id": "NCT02763384", "title": "BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-Acute Lymphoblastic Leukemia", "Adult T Lymphoblastic Lymphoma" ], "interventions": [ { "name": "BL-8040", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2016-12-02", "completion_date": "2022-05-22", "has_results": true, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 2, "location_summary": "St Louis, Missouri • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02763384" }, { "nct_id": "NCT00248547", "title": "Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "aprepitant", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-05", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248547" }, { "nct_id": "NCT04572763", "title": "Copanlisib Plus Venetoclax in R/R DLBCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Relapsed Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-09-08", "completion_date": "2026-07-29", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 3, "location_summary": "Duarte, California • Boston, Massachusetts • St Louis, Missouri", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572763" }, { "nct_id": "NCT06247787", "title": "A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Myelodysplastic Syndrome", "Recurrent Juvenile Myelomonocytic Leukemia", "Refractory Childhood Acute Myeloid Leukemia", "Refractory Childhood Myelodysplastic Syndrome", "Refractory Juvenile Myelomonocytic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Imetelstat", "type": "BIOLOGICAL" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 36, "start_date": "2025-02-04", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06247787" }, { "nct_id": "NCT05169489", "title": "A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "bbT369", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-01-24", "completion_date": "2025-09-19", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 4, "location_summary": "Stanford, California • Denver, Colorado • Tampa, Florida + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169489" }, { "nct_id": "NCT03057990", "title": "Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Pyrimethamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-09-11", "completion_date": "2021-06-29", "has_results": false, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03057990" }, { "nct_id": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Gene Mutation", "HER-2 Gene Amplification", "HER2 Positive Gastric Cancer", "Salivary Gland Cancer", "Salivary Gland Tumor", "Salivary Gland Carcinoma", "Salivary Gland Neoplasms", "Lung Cancer", "Colo-rectal Cancer", "Rare Diseases", "Solid Tumor", "Recurrent Gastric Cancer", "Recurrent Colon Cancer", "Recurrent Breast Cancer", "Head and Neck Cancer", "Head and Neck Carcinoma", "Bladder Cancer", "Cervical Cancer", "Liver Cancer", "Bile Duct Cancer", "Urologic Cancer", "Pancreatic Cancer", "Prostate Cancer", "Recurrent Prostate Cancer", "Rectal Cancer", "Recurrent Ovarian Carcinoma", "Recurrent Renal Cell Cancer", "Rectal Cancer Stage II", "Rectal Cancer Stage I", "Rectal Cancer Stage III", "Skin Cancer", "Mouth Cancer", "Lip Cancer Stage I", "Tongue Cancer", "Breast Neoplasm Malignant Primary", "Larynx Cancer", "Tonsil Cancer", "Palate Cancer", "Mucoepidermoid Carcinoma", "Primary Peritoneal Carcinoma", "Mucinous Adenocarcinoma Gastric", "Mucinous Breast Cancer Recurrent", "Cholangiocarcinoma" ], "interventions": [ { "name": "A166", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Klus Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-07-16", "completion_date": "2022-01-12", "has_results": false, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 10, "location_summary": "Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03602079" }, { "nct_id": "NCT04105010", "title": "Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "golidocitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dizal Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2019-09-10", "completion_date": "2024-02-22", "has_results": true, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-11-13T01:09:27.886Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04105010" } ] }